*ALMIRALL AND ABSCI EXPAND AI DRUG CREATION COLLABORATION ADDING SECOND DERMATOLOGY TARGET
*ABSCI ELIGIBLE FOR UP TO $650 MILLION IN PAYMENTS
*SELECTS SECOND TARGET AIMED AT DERMATOLOGICAL INDICATIONS IN AI DRUG COLLABORATION
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 07-AUG-202506:00:00.263 GMT